Skip to main content

Table 2 Mutational status of the samples selected for the first (A-label) and the second (B-label) round of the EQA

From: The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences

Sample ID

KRASa

BRAFa

NRASa

A1

WT

WT

WT

A2

WT

WT

WT

A3

WT

WT

WT

A4

WT

WT

WT

A5

WT

WT

WT

A6

WT

p.V600E (c.1799T > A) (27.6 %)

WT

A7

p.A146T (c.436G > A) (27.6 %)

WT

WT

A8

p.G12D (c.35G > A) (24.2 %)

WT

WT

A9

WT

WT

p.G12D (c.35G > A) (18.1 %)

A10

WT

WT

p.Q61K (c.181C > A) (74.6 %)

B1

WT

WT

WT

B2

WT

WT

WT

B3

WT

WT

WT

B4

WT

WT

WT

B5

WT

WT

WT

B6

p.G12D (c.35G > A) (27.7 %)

WT

WT

B7

p.A146T (c.436G > A) (62 %)

WT

WT

B8

WT

WT

p.Q61R (c.182A > G) (29.5 %)

B9

WT

WT

p.G12S (c.34G > A) (45.2 %)

B10

WT

p.V600E (c.1799T > A) (36.9 %)

WT

  1. aIn parentheses it is indicated the percentage of allele frequency evaluated by means of Ion Torrent